Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Atropine was proven to be effective in controlling myopia. 7‐methylxanthine was considered to play a role in slowing myopia. The experimental BHVI2 eye drops were proven to be safe for in‐eye use in the trial that was conducted in Sydney, Australia. The investigators wish to evaluate the effects of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination mainly on the pupillary and accommodative responses in children aged between 6 to 13 years old over a one‐month period.
Epistemonikos ID: b47b24e3713e342c7ea8c6f4ab89b77549b185c2
First added on: May 21, 2024